Table 7.
Mean (SD) weighted MDG at baseline and after administration of oral empagliflozin doses (2.5–100 mg) without an oral glucose tolerance test
| Empagliflozin dose | Number of patients | Mean MDG (SD) mg/dL | |||
|---|---|---|---|---|---|
| Baseline (day −2) | Day 8 | Mean (least squares) change from baseline to day 8 | Difference to placebo | ||
| Placebo | 12a | 169 (30.5) | 153 (24.5) | −13.5 | |
| 2.5 mg qd | 9 | 161 (57.3) | 134 (42.7) | −29.0 | −15.5, p < 0.05 |
| 10 mg qd | 9b | 160 (35.8) | 124 (18.9) | −37.0 | −23.5, p < 0.01 |
| 25 mg qd | 9 | 159 (32.8) | 133 (36.2) | −28.5 | −15.0, p = 0.052 |
| 100 mg qd | 9 | 185 (33.0) | 154 (17.9) | −24.1 | −10.6, p = 0.168 |
Data from the treated analysis set (n = 48). Weighted MDG, weighted mean daily glucose estimated by dividing the area under the 24-h glucose curve by 24 h for each patient on each day
SD standard deviation
a n = 11 on day 8
b n = 8 on day 8